{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:18Z","timestamp":1792001538073,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca Spain, Spain"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of this study was to carry\u00a0out a cost-effectiveness analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), for the treatment of type 2 diabetes mellitus (T2DM) in Spain, based on the results of the DECLARE-TIMI 58 trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A discrete event simulation model (Cardiff T2DM) based on the data observed in the DECLARE-TIMI 58 trial was adapted to the Spanish setting to estimate the costs and health outcomes of treatment with dapagliflozin in patients with T2DM who had or were at risk of atherosclerotic cardiovascular disease. Macrovascular events (hospitalization for heart failure, myocardial infarction, stroke, and unstable angina), end-stage renal disease and cardiovascular and non-cardiovascular mortality were modeled according to the survival equations of the DECLARE-TIMI 58 study. Microvascular events (blindness and ulcers) were estimated based on the risk equations of the UK Prospective Diabetes Study. The analysis was conducted from the Spanish National Health System perspective and the time horizon was 30 years. The results were evaluated in terms of cost per quality-adjusted life year (QALY) gained. Only direct health costs were included, and a 3% discount rate was applied to costs and health outcomes. Univariate and probabilistic sensitivity analyses (PSA) were made to assess the robustness of the results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the main analysis, dapagliflozin was a dominant therapeutic option compared with placebo, with greater effectiveness (0.08 QALYs) and lower associated total costs per patient (\u20ac -2,921). The univariate sensitivity analysis and the PSA confirmed the robustness of the results. The PSA showed the probability that dapagliflozin was a dominant alternative compared with placebo was 84.2% and that it was cost-effective of 92.1%, under a willingness-to-pay of \u20ac 20,000\/QALY gained. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The analysis of data from the DECLARE-TIMI 58 trial shows that dapagliflozin would be a cost-effective option in Spain for the treatment of adult patients with T2DM, as an add-on therapy to SoC, compared with placebo.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-07567-5","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:03:19Z","timestamp":1645095799000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study"],"prefix":"10.1186","volume":"22","author":[{"given":"Carlos","family":"Escobar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3bal","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Capel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"P\u00e9rez-Alc\u00e1ntara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisenda","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"7567_CR1","unstructured":"Mu\u00f1oz Grimaldo M. La enfermera de Primaria y la Diabetes. Gu\u00eda de la RedGDPS. Epidemiolog\u00eda, prevenci\u00f3n y criterios diagn\u00f3sticos y de control. 2011. http:\/\/www.redgdps.org\/la-enfermera-de-primaria-y-la-diabetes-20161003. Accessed 21 Jan 2021."},{"key":"7567_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.avdiab.2013.07.007","volume":"29","author":"C Crespo","year":"2013","unstructured":"Crespo C, Brosa M, Soria-Juan A, Lopez-Alba A, L\u00f3pez-Mart\u00ednez N, Soria B. Direct cost of diabetes mellitus and its complications in Spain (SECCAID Study: Spain estimated cost Ciberdem-Cabimer in Diabetes). Avances en Diabetolog\u00eda. 2013;29:182\u20139.","journal-title":"Avances en Diabetolog\u00eda"},{"key":"7567_CR3","unstructured":"Hidalgo A, Oliva J, Rubio M, Zozaya N, Villoro R, Garc\u00eda S. Estudios de coste de la diabetes tipo 2: una revisi\u00f3n de la literatura. 2015. http:\/\/gesdoc.isciii.es\/gesdoccontroller?action=download&id=26\/05\/2015-28ff538b32. Accessed 21 Jan 2021."},{"key":"7567_CR4","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Estrategia en Diabetes del Sistema Nacional de Salud. Madrid; 2012."},{"key":"7567_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","volume":"55","author":"F Soriguer","year":"2012","unstructured":"Soriguer F, Goday A, Bosch-Comas A, Bordi\u00fa E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55:88\u201393.","journal-title":"Diabetologia"},{"key":"7567_CR6","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1038\/s41598-020-59643-7","volume":"10","author":"G Rojo-Mart\u00ednez","year":"2020","unstructured":"Rojo-Mart\u00ednez G, Vald\u00e9s S, Soriguer F, Vendrell J, Urrutia I, P\u00e9rez V, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Scientific Reports. 2020;10:2765.","journal-title":"Scientific Reports"},{"key":"7567_CR7","unstructured":"Fundaci\u00f3n redGDPS. Gu\u00eda de diabetes tipo 2 para cl\u00ednicos: Recomendaciones de la redGDPS. 2018."},{"key":"7567_CR8","doi-asserted-by":"crossref","unstructured":"Gomez-Peralta F, Escalada San Mart\u00edn FJ, Men\u00e9ndez Torre E, Mata Cases M, Ferrer Garc\u00eda JC, Ezkurra Loiola P, et al. Recomendaciones de la Sociedad Espa\u00f1ola de Diabetes (SED) para el tratamiento farmacol\u00f3gico de la hiperglucemia en la diabetes tipo 2: Actualizaci\u00f3n 2018. Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n. 2018;65:611\u201324.","DOI":"10.1016\/j.endinu.2018.08.004"},{"key":"7567_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2019;380:347\u201357.","journal-title":"New England Journal of Medicine"},{"key":"7567_CR10","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747\u201359.","journal-title":"Diabetologia"},{"key":"7567_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925\u201333.","journal-title":"Diabetologia"},{"key":"7567_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet. 1998;352:837\u201353.","journal-title":"The Lancet"},{"key":"7567_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","volume":"16","author":"AJ Palmer","year":"2013","unstructured":"Palmer AJ. Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting. Value in Health. 2013;16:670\u201385.","journal-title":"Value in Health"},{"key":"7567_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12962-015-0038-8","volume":"13","author":"P McEwan","year":"2015","unstructured":"McEwan P, Ward T, Bennett H, Bergenheim K. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Effectiveness and Resource Allocation. 2015;13:12.","journal-title":"Cost Effectiveness and Resource Allocation"},{"key":"7567_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40273-014-0225-z","volume":"33","author":"P McEwan","year":"2015","unstructured":"McEwan P, Bennett H, Ward T, Bergenheim K. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. PharmacoEconomics. 2015;33:149\u201361.","journal-title":"PharmacoEconomics"},{"key":"7567_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1185\/030079906X80350","volume":"22","author":"P McEwan","year":"2006","unstructured":"McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research and Opinion. 2006;22:121\u20139.","journal-title":"Current Medical Research and Opinion"},{"key":"7567_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/dom.13217","volume":"20","author":"I Raz","year":"2018","unstructured":"Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, et al. DECLARE-TIMI 58: Participants\u2019 baseline characteristics. Diabetes, Obesity and Metabolism. 2018;20:1102\u201310.","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"7567_CR18","unstructured":"Ortega Eslava A, Mar\u00edn Gil R, Fraga Fuentes MD, L\u00f3pez-Briz E, Puigvent\u00f3s Latorre F. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos. 2016."},{"key":"7567_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s13300-019-00744-6","volume":"11","author":"GP Fadini","year":"2020","unstructured":"Fadini GP, Tentolouris N, Caballero Mateos I, Bellido Casta\u00f1eda V, Morales Portillo C. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe. Diabetes Therapy. 2020;11:423\u201336.","journal-title":"Diabetes Therapy"},{"key":"7567_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0025-7753(17)30618-8","volume":"147","author":"J Franch Nadal","year":"2016","unstructured":"Franch Nadal J, Mata Cases M, Mauricio Puente D. Epidemiolog\u00eda y control cl\u00ednico de la diabetes mellitus tipo 2 y sus comorbilidades en Espa\u00f1a (estudio e-Control). Medicina Cl\u00ednica. 2016;147:1\u20137.","journal-title":"Medicina Cl\u00ednica"},{"key":"7567_CR21","unstructured":"Mosenzon O, Dwyer J, Cahn A, Goodrich E, Murphy S, Rozenberg A, et al. TH-PO1205: Prevention of chronic kidney disease with dapagliflozin: analysis of the DECLARE-TIMI 58 trial. In: ASN Kidney week 2019. 2019."},{"key":"7567_CR22","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Portal Farma. BotPLUS. 2021. https:\/\/botplusweb.portalfarma.com\/botplus.aspx."},{"key":"7567_CR23","unstructured":"World Health Organization. ATC\/DDD Index 2021. WHO Collaborating Centre for Drug Statistics Methodology. 2021. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 25 Jan 2021."},{"key":"7567_CR24","unstructured":"Ministerio de Sanidad Consumo y Bienestar Social. Conjunto M\u00ednimo B\u00e1sico de Datos (CMBD). Registro de Atenci\u00f3n Especializada. 2021. http:\/\/pestadistico.inteligenciadegestion.msssi.es\/. Accessed 26 Jan 2021."},{"key":"7567_CR25","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.aprim.2014.11.002","volume":"47","author":"EJ Abad Paniagua","year":"2015","unstructured":"Abad Paniagua EJ, Casado Escribano P, Fern\u00e1ndez Rodriguez JM, Morales Escobar FJ, Beteg\u00f3n Nicol\u00e1s L, S\u00e1nchez-Covisa J, et al. An\u00e1lisis de coste-efectividad de dapagliflozina en comparaci\u00f3n con los inhibidores de la DPP4 y otros antidiab\u00e9ticos orales en el tratamiento de la diabetes mellitus tipo 2 en Espa\u00f1a. Atenci\u00f3n Primaria. 2015;47:505\u201313.","journal-title":"Atenci\u00f3n Primaria"},{"key":"7567_CR26","first-page":"747","volume":"35","author":"A Abej\u00f3n Arroyo","year":"2012","unstructured":"Abej\u00f3n Arroyo A, \u00c1laverz V\u00e1zquez J, Blasco Garc\u00eda C, Bermejo Mart\u00ednez M, L\u00f3pez Casanova P, Cuesta Cuesta J, et al. Coste-Efectividad de un ap\u00f3sito de espuma de poliuretano con TLC-NOSF. Estudio en el tratamiento de las \u00falceras venosas de pierna. Revista Rol de Enfermer\u00eda. 2012;35:747\u201352.","journal-title":"Revista Rol de Enfermer\u00eda"},{"key":"7567_CR27","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Documento Marco sobre Enfermedad Renal Cr\u00f3nica (ERC) dentro de la Estrategia de Abordaje a la Cronicidad en el SNS. 2015."},{"key":"7567_CR28","unstructured":"Cabellero Alcalde C, Calleja Hern\u00e1ndez M, Escoda Ruiz L, Espasa Triquell N, Est\u00e9vez Lucas J, Fraga Rodr\u00edguez G, et al. Libro Blanco de la Poliquistosis Renal Autos\u00f3mica Dominante (PQRAD) en Espa\u00f1a. 2nd edition. 2016."},{"key":"7567_CR29","unstructured":"Gisbert R, Brosa M. Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud. Barelona, Spain; 2020."},{"key":"7567_CR30","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s13300-017-0285-0","volume":"8","author":"W Parekh","year":"2017","unstructured":"Parekh W, Hoskins N, Baker-Knight J, Ramirez de Arellano A, Mezquita Raya P. The Economic Burden of Insulin-Related Hypoglycemia in Spain. Diabetes Therapy. 2017;8:899\u2013913.","journal-title":"Diabetes Therapy"},{"key":"7567_CR31","first-page":"291","volume":"26","author":"R Pons","year":"2006","unstructured":"Pons R, Torregrosa E, Hern\u00e1ndez-Jaras J, Garc\u00eda H, Rius A, Calvo C, et al. El coste del tratamiento farmacol\u00f3gico en la enfermedad renal cr\u00f3nica. Nefrolog\u00eda. 2006;26:291\u2013414.","journal-title":"Nefrolog\u00eda"},{"key":"7567_CR32","doi-asserted-by":"crossref","unstructured":"Darb\u00e0 J, Mars\u00e0 A. Chronic kidney disease in Spain: analysis of patient characteristics, incidence and direct medical costs (2011\u20132017). Journal of Medical Economics. 2020;:1\u20137.","DOI":"10.1080\/13696998.2020.1830782"},{"key":"7567_CR33","first-page":"458","volume":"34","author":"V Lorenzo-Sellares","year":"2014","unstructured":"Lorenzo-Sellares V, Pedrosa MI, Santana-Exp\u00f3sito B, Garc\u00eda-Gonz\u00e1lez Z, Barroso-Montesinos M. Cost analysis and sociocultural profile of kidney patients. Impact of the treatment method. Nefrologia. 2014;34:458\u201368.","journal-title":"Nefrologia"},{"key":"7567_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.endonu.2013.05.005","volume":"61","author":"P DePablos-Velasco","year":"2014","unstructured":"DePablos-Velasco P, Salguero-Chaves E, Mata-Poyo J, DeRivas-Otero B, Garc\u00eda-S\u00e1nchez R, Viguera-Ester P. Calidad de vida y satisfacci\u00f3n con el tratamiento de sujetos con diabetes tipo 2: resultados en Espa\u00f1a del estudio PANORAMA. Endocrinolog\u00eda y Nutrici\u00f3n. 2014;61:18\u201326.","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n"},{"key":"7567_CR35","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D Scores for the United Kingdom. Medical Decision Making. 2011;31:800\u20134.","journal-title":"Medical Decision Making"},{"key":"7567_CR36","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","volume":"17","author":"A Beaudet","year":"2014","unstructured":"Beaudet A, Clegg J, Thuresson P-O, Lloyd A, McEwan P. Review of Utility Values for Economic Modeling in Type 2 Diabetes. Value in Health. 2014;17:462\u201370.","journal-title":"Value in Health"},{"key":"7567_CR37","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/027298902400448902","volume":"22","author":"P Clarke","year":"2002","unstructured":"Clarke P, Gray A, Holman R. Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62). Medical Decision Making. 2002;22:340\u20139.","journal-title":"Medical Decision Making"},{"key":"7567_CR38","first-page":"49","volume":"44","author":"HC Barry","year":"1997","unstructured":"Barry HC, Ebell MH, Hickner J. Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies. The Journal of family practice. 1997;44:49\u201360.","journal-title":"The Journal of family practice"},{"key":"7567_CR39","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/j.1523-1755.2005.00752.x","volume":"68","author":"I Gorodetskaya","year":"2005","unstructured":"Gorodetskaya I, Zenios S, Mcculloch CE, Bostrom A, Hsu C-Y, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney International. 2005;68:2801\u20138.","journal-title":"Kidney International"},{"key":"7567_CR40","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1185\/03007995.2014.899207","volume":"30","author":"S Lane","year":"2014","unstructured":"Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Current Medical Research and Opinion. 2014;30:1267\u201373.","journal-title":"Current Medical Research and Opinion"},{"key":"7567_CR41","doi-asserted-by":"crossref","unstructured":"Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR): Descriptive Analysis from the First 20,000 Subjects. Value in Health. 2005;8:581\u201390.","DOI":"10.1111\/j.1524-4733.2005.00046.x"},{"key":"7567_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.910","volume":"14","author":"A Bagust","year":"2005","unstructured":"Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Economics. 2005;14:217\u201330.","journal-title":"Health Economics"},{"key":"7567_CR43","volume-title":"Disposici\u00f3n a pagar de la sociedad espa\u00f1ola por un A\u00f1o de Vida Ajustado por Calidad","author":"L Vallejo-Torres","year":"2016","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Rivero-Arias O, Pinto-Prades J, Serrano-Aguilar P. Disposici\u00f3n a pagar de la sociedad espa\u00f1ola por un A\u00f1o de Vida Ajustado por Calidad. Santa Cruz de Tenerife: Servicio Canario de la Salud; 2016."},{"key":"7567_CR44","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jval.2013.02.010","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in Health. 2013;16:e1\u20135.","journal-title":"Value in Health"},{"key":"7567_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14308","author":"P McEwan","year":"2020","unstructured":"McEwan P, Morgan AR, Boyce R, Bergenheim K, Gause-Nilsson IAM, Bhatt DL, et al. The cost\u2010effectiveness of dapagliflozin in treating high\u2010risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE\u2010TIMI 58 trial. Diabetes, Obesity and Metabolism. 2020. https:\/\/doi.org\/10.1111\/dom.14308.","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"7567_CR46","first-page":"A350","volume":"17","author":"J S\u00e1nchez-Covisa","year":"2014","unstructured":"S\u00e1nchez-Covisa J, Capel M, Schmidt R, Charokopou M, Verheggen BG. The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain. Value in Health. 2014;17:A350.","journal-title":"Value in Health"},{"key":"7567_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/2018374","volume":"2019","author":"S Canivell","year":"2019","unstructured":"Canivell S, Mata-Cases M, Vlacho B, Gratac\u00f2s M, Real J, Mauricio D, et al. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. Journal of Diabetes Research. 2019;2019:1\u20139.","journal-title":"Journal of Diabetes Research"},{"key":"7567_CR48","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1111\/dom.13852","volume":"21","author":"A Norhammar","year":"2019","unstructured":"Norhammar A, Bodegard J, Nystr\u00f6m T, Thuresson M, Rikner K, Nathanson D, et al. Dapagliflozin vs non-SGLT\u20102i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE\u2010TIMI 58 trial: A nationwide observational study. Diabetes, Obesity and Metabolism. 2019;21:2651\u20139.","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"7567_CR49","doi-asserted-by":"crossref","unstructured":"Morieri ML, Consoli A, Sesti G, Purrello F, Avogaro A, Fadini GP. Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world. Diabetes\/Metabolism Research and Reviews. 2021;37.","DOI":"10.1002\/dmrr.3353"},{"key":"7567_CR50","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00125-018-4806-9","volume":"62","author":"SJ McGurnaghan","year":"2019","unstructured":"McGurnaghan SJ, Brierley L, Caparrotta TM, McKeigue PM, Blackbourn LAK, Wild SH, et al. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia. 2019;62:621\u201332.","journal-title":"Diabetologia"},{"key":"7567_CR51","doi-asserted-by":"crossref","unstructured":"Persson F, Nystr\u00f6m T, J\u00f8rgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD\u2010REAL Nordic) when compared with dipeptidyl peptidase\u20104 inhibitor therapy: A multinational observational study. Diabetes, Obesity and Metabolism. 2018;20:344\u201351.","DOI":"10.1111\/dom.13077"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-07567-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-07567-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-07567-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:14:18Z","timestamp":1645096458000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-07567-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7567"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-07567-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Research ethics was not required as the study did not involve human subjects or materials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC and SS are employed by AstraZeneca Spain. FP and EP are employed by Oblikue Consulting, a consultant company specialized in economic evaluations of health interventions and received financial support from AstraZeneca Spain for the development of this study.  CE and CM received an honorarium from the sponsor and participated as independent consultants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}